These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29696765)

  • 1. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT2 Inhibitors and Euglycemic Ketoacidosis.
    Masuta P; Johri G; Paul M
    Am J Ther; 2018; 25(4):e498-e500. PubMed ID: 28537992
    [No Abstract]   [Full Text] [Related]  

  • 3. Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes.
    Khan N; Tso K; Broussard J; Dziuba M
    Am J Health Syst Pharm; 2019 Nov; 76(23):1930-1933. PubMed ID: 31724039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.
    Koch RA; Clark RF
    Am J Ther; 2018; 25(5):e590-e591. PubMed ID: 28452848
    [No Abstract]   [Full Text] [Related]  

  • 5. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].
    Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D
    Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123
    [No Abstract]   [Full Text] [Related]  

  • 6. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
    [No Abstract]   [Full Text] [Related]  

  • 7. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons from the bedside: ketoacidosis and SGLT2 inhibitors.
    Chow YY; Worsley R; Topliss DJ
    Med J Aust; 2016 Aug; 205(4):191-2. PubMed ID: 27510353
    [No Abstract]   [Full Text] [Related]  

  • 9. Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor.
    Zhang L; Tamilia M
    CMAJ; 2018 Jun; 190(25):E766-E768. PubMed ID: 29941433
    [No Abstract]   [Full Text] [Related]  

  • 10. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
    Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
    Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin.
    van Niekerk C; Wallace J; Takata M; Yu R
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30131409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Nov; 193(45):E1746-E1749. PubMed ID: 34782384
    [No Abstract]   [Full Text] [Related]  

  • 13. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
    Jazi M; Porfiris G
    Can Fam Physician; 2016 Sep; 62(9):722-4. PubMed ID: 27629667
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Unusual Case of Metabolic Acidosis: Clinical Case Education.
    Abu-Amer N; Dinour D; Mini S; Beckerman P
    Isr Med Assoc J; 2019 Nov; 21(11):766-768. PubMed ID: 31713370
    [No Abstract]   [Full Text] [Related]  

  • 16. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fournier's Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications.
    Kasbawala K; Stamatiades GA; Majumdar SK
    Am J Case Rep; 2020 Jun; 21():e921536. PubMed ID: 32483108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
    Menghoum N; Oriot P; Hermans MP; Mariage JL
    Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
    Messana JA; Schwartz SS; Townsend RR
    Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?
    Abate N; Chandalia M
    Metab Syndr Relat Disord; 2016 Feb; 14(1):1-2. PubMed ID: 26554527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.